Latest Regulatory News

Biotron Limited reveals that its lead antiviral candidate BIT-HBV001 shows promising activity against Hepatitis Delta Virus, expanding its potential impact beyond Hepatitis B. Meanwhile, the company completes integration of Sedarex and advances regulatory plans for its anaesthetic SedRx.

OZZ Resources Limited has announced a fully underwritten entitlement offer to raise approximately $1.07 million, aiming to convert debt and fund project opportunities while addressing its ongoing ASX suspension. The offer carries significant risks including potential dilution and the threat of delisting if compliance is not met by June 2026.

Strike Resources has agreed to sell a further 28.52% indirect stake in its Apurimac Iron Ore Project to JE United Ltd for A$5.5 million, while securing a US$5 million credit facility to accelerate project development and iron ore marketing.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

Sequoia Financial Group is actively reviewing its retail licensee services, focusing on its subsidiary InterPrac Financial Planning, with potential structural changes or a sale under consideration amid shifting platform provider relationships.

Bank of Queensland Limited announces a fully franked quarterly distribution of AUD 1.3218 per Capital Note 3 security, payable mid-June 2026. The distribution reflects a 5.3% annualised rate tied to the 3-month BBSW plus margin.

Vulcan Energy has obtained its inaugural lithium production licence for the Lionheart Project in Germany, marking a pivotal step as the project moves into funded construction. This licence supports Vulcan’s ambition to supply Europe with sustainable lithium for electric vehicle batteries, backed by renewable energy co-production.

Ark Mines Limited has secured a crucial mining licence for its Sandy Mitchell Rare Earths Project in North Queensland, marking a key step toward development and commercialisation.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Clarity Pharmaceuticals has unveiled compelling Phase II trial results showing its Cu-SAR-bisPSMA PET imaging agent significantly improves detection of prostate cancer recurrence over the current standard. The data, presented at the 2026 European Association of Urology Congress and accepted by European Urology journal, mark a key milestone ahead of regulatory submissions.

Siren Gold’s latest drilling at its Sams Creek Project in New Zealand confirms significant gold mineralisation outside the established Main Zone, highlighting promising expansion potential along the 7km Sams Creek Dyke.

Vitura Health has inked a binding distribution agreement with MedReleaf Australia, unlocking access to a broad medicinal cannabis portfolio across its extensive pharmacy network. This deal could add up to AUD 15 million annually, positioning Vitura as a dominant player in the evolving Australian market.